New Phase Ib myeloma study registered; GSK-linked FTD trial terminated, BRCA study posted

GSK appears as collaborator or partner across three separate registry updates this period, ranging from a newly registered study to a terminated trial and a study with posted results.

• A new Phase Ib study, sponsored by the Canadian Myeloma Research Group with GSK and Hoffmann-La Roche as collaborators, was posted as "not yet recruiting." The trial will test belantamab mafodotin in combination with cevostamab and pomalidomide in patients with multiple myeloma who have relapsed disease after two or more lines of therapy and/or have refractory to treatment disease.¹ The study is estimated to enroll 108 participants¹.
• Alector's Phase 3 trial of AL001 in frontotemporal dementia due to progranulin gene mutations, listed as "INFRONT-3," was marked terminated. The study record states it did not meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating® plus National Alzheimer's Coordinating Center Frontotemporal Lobar Degeneration Sum of Boxes (CDR® plus NACC FTLD-SB)². GSK is listed as a collaborator, with Alector Inc. as lead sponsor.
• Dana-Farber Cancer Institute posted results for a Phase II study of niraparib plus dostarlimab as neoadjuvant treatment in patients with BRCA-mutated breast cancer, with GSK as a collaborator. The trial had enrollment: 66 participants (actual)³ across Stage I Breast Cancer; Stage II Breast Cancer; Stage III Breast Cancer³, and participants will receive treatment for 18 weeks³.